Cystic lesions of the pancreas are a common entity with almost a 25% incidence of the general population. These types of lesions are being increasingly diagnosed partly explained due to the technological advances over the past years. The management and treatment varies per cyst type. However, the most threatening cyst lesions are intraductal papillary mucinous neoplasms (IPMNs). These lesions represent nowadays a relatively new clinical entity and in many aspects remain poorly understood. The aim of this chapteristoprovideacomprehensivereviewoftheclassification,diagnosis,treatment and follow-up strategy.
Introduction
In the face of this new "epidemic of pancreatic cysts," it is clear that we need to be on top of newly emerging changes in our current daily practice. Pancreatic cancer has a fateful prognosis, despite recent improvements in surgery and chemotherapy. However, most cases of intraductal papillary mucinous neoplasms (IPMNs) are considered as premalignant lesions, thusmakingthematargetfordiagnosisandprompttreatment.Ontheotherhand,weshould neverforgettheshort-andlong-termrisksofsurgery.Thisispreciselywhyitissochallenging to adequately manage this pathology.
Biomarkers represent an interesting opportunity, but until they can be used on a regular clinical basis, we are obliged to say knowledgeable on new insights involving radiologic characteristics and potential malignancy prior to deciding, which is the best available individualized option for each patient.
Classification

Anatomic classification: involvement of the pancreatic ductal system
Most IPMN arise from the pancreatic main duct or its branch ducts (Figure 1) . Most of thesetumorsareunifocal,20-30%aremultifocal,and5-10%oftheIPMNdiffuselyaffect the entire duct system of the pancreas. Depending on the involvement of the pancreatic duct, IPMNs are classified as either main duct IPMN (MD-IPMN) or branch duct IPMN (BD-IPMN). If both, main and branch ducts are involved together, then it is defined as combined-type IPMN (Figure 2) . The clinical pathologic behavior of combined-type IPMN is similar to that of MD-IPMN. MD-IPMN is frequently more associated with this malignant transformation than is BD-IPMN, requiring surgical resection in more than a half of the patients, while most patients with BD-IPMN can be observed for a long time after the diagnosis. 
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Histologic classification: IPMN subtype
Immunohistochemicalstainingwithmucinantibodiesenablesdifferentiationbetweentumors withdifferentprognoses.FoursubtypesofIPMNshavebeencharacterized:gastric,intestinal, pancreatobiliary, and oncocytic. Most of BD-IPMNs are composed of gastric-type epithelium. However, intestinal type is more common in MD-IPMN. In a recent report, the four subtypes ofIPMNswereassociatedwithsignificantdifferencesinsurvival.Patientswithgastric-type IPMN had the best prognosis, whereas those with intestinal and pancreatobiliary type had a bad prognosis [1] [2] [3] [4] [5] [6] .
World Health Organization (WHO)
TheWorldHealthOrganization(WHO)classifiedIPMNsintothreesubgroupsaccordingto degree of dysplasia: (I) IPMN with low-or intermediate-grade dysplasia; (II) IPMN with highgrade dysplasia (carcinoma in situ); and (III) IPMN with an associated invasive carcinoma. IPMN associated with PDAC (pancreatic ductal adenocarcinoma arising in association with an IPMN) was further classified into two subtypes: tubular adenocarcinoma, composed of predominantlygland-formingneoplasticcellswithfibroticstromaandabsenceof significant extracellular stromal mucin and colloid carcinoma (mucinous noncystic carcinoma), composed of sparsely populated strips, clusters, or individual neoplastic cells residing within extensive pools of extracellular mucin [6] . In case of IPMN with low-to intermediate-grade of dysplasia, dysplastic changes in the columnar cells are minimal or absent. The prognosis is usually favorable [7] .
Malignancy risk
There has been an increased prevalence of pancreatic cystic neoplasms, frequently being found in elderly asymptomatic patients. This is partially caused by the greater number of cross-sectional studies being performed. Though images obtained through the use of computed tomography (CT-scan) and magnetic resonance imaging (MRI), we are able to estimate the prevalence ofpancreaticcystsin2.5%ofthepopulation.Thisfigureincreasesovertime;aroundtheageof 70 years or older, 10% of the population has pancreatic cysts and 20-50% of them are IPMN [8] .
Therealriskofmalignancymaybeverylow,butthediagnosisisassociatedwithanxiety andusuallyleadstofurthermedicaltestinginordertoconfirmmalignancy.Themostfrequentlyusedtestsarelikelytoinclude:consultationscongastroenterologistsand/oroncologists, endoscopic ultrasound with or without percutaneous biopsy, and occasionally surgery [6, 8, 9] . This is one of the reasons why more and more studies are focusing on evaluating the malignancy rate for pancreatic cancer distinct from IPMN and also for pancreatic cancer arisingfromIPMN.Figuresarerathervariable,butoverthecourseofseveralyears,wehave been able to see how the rates for malignancy, especially in SB-IPMN, are found to be lower.
Not only IMPNs are associated with pancreatic malignancies but also it is known that extrapancreatic malignancies are more frequently found in these patients.
Pancreatic malignancies
Pancreatic cancer arising from IPMN
MD-IPMN
Themalignancyriskinthistypeofsituationisveryclearwhichmakesthedecisiontoperform surgeryalsomucheasier.Manystudieshaveestimatedtheoverallriskrangesbetween36and 92% [10] [11] [12] [13] .Overall,theprognosisafterresectionisgenerallyfavorableaslongasitsinvasion remains within minimally invasive or in T1a status (depth of stromal invasion <5 mm).
BD-IPMN
Inthiscase,therearemorecontroversialfigures.Estimatedratesherecanrangefrom6to47% [8, [11] [12] [13] . In 2013, Gardner et al. [8] lowerthecurrent25%lifetimeriskofmalignanttransformation and presented the prevalence of mucin-producing adenocarcinoma in patients diagnosed with pancreatic cysts to be 33.2 per 100,000 patients. A linear increment was detected whenstudyingmalepatientsbetweentheagesof80-84.Inthatgroup,theprevalencewas 38.6per100,000patients.OnlyonesystematicreviewbyCrippaetal. [14] is considered to be thefirstmeta-analysesfocusedintheriskofdevelopingpancreaticmalignancies,including malignantBD-IPMNsandPDAC,aswellastheriskofdeathduetopancreaticmalignancy in patients undergoing nonoperative management for BD-IPMNs. The estimated overall pancreatic malignancy rate is 3.7%, an incidence of malignancy in 7 cases per 1000 per years andanannualriskononly0.7%.Thisistheratethatisentirelycomparablewiththe90-day postoperative mortality rate following pancreatic resections found at many high-volume centers.Thus,choosingsurgeryinthesecasesdoesnotjustifyforavoidingtheunlikelyprogressionfrom"low-risk"BD-IPMNtoinvasivetumors.
Pancreatic cancer distinct from IPMN
Thereappearstobea"fielddefect,"whichmaygiverisetobothIPMNandpancreaticduct adenocarcinoma (frequently related to gastric subtype) occurring in 2-5% of patients diagnosed with IPMN [6, 10] . Also, Crippa et al. [14] lower the previous rates with an estimate of incidenceofonly2casesper1000peryearandanannualriskof0.2%.
Extrapancreatic malignancies
Colorectal, gastric, bile duct, renal cell, and thyroid cancers are relatively frequently associated with IPMNs [15] [16] [17] .
Pathogenesis
IPMNs are mucinous cystic lesions of the pancreas that are characterized by neoplastic, mucin-secreting, and papillary cells projecting from the pancreatic ductal surface. They arise from the epithelial lining of the main pancreatic duct or its side branches. Intraductal proliferation of mucin-producing columnar cells is the main histologic characteristic of IPMNs, and intraluminal growth causes dilatation of the involved duct and its proximal segment. They are usually found in the head of the pancreas as a solitary cystic lesion, but in 20-30% of the cases,theymaybemultifocal,andin5-10%ofcases,theymayinvolvethepancreasdiffusely [18] [19] [20] .InBD-IPMN,malignanttumorscanbefoundin6-46%andinMD-IPMNin57-92%, makingthatMD-IPMNleadstoworseprognosis [5] .
Progression to pancreatic cancer
IPMNs are thought to follow an orderly progression from a benign neoplasm to invasive carcinoma of the pancreas, they range from premalignant lesions with low-grade dysplasia to invasive malignancy, and they have a clear tendency to become invasive carcinoma [5, [21] [22] [23] [24] . Ithasbeenestimateda5-6yearprogressionrate,dependingonthesubtype.Theyaregraded according to the most atypical area in the lesion as:
• Low-grade dysplasia (adenoma).
• Moderate dysplasia (borderline).
• High-grade dysplasia (carcinoma in situ).
• Invasive carcinoma.
Clinical presentation
Risk factors
It has been described that previous history of diabetes, especially with insulin dependency, chronic pancreatitis, or a familial history of pancreatic ductal adenocarcinoma (PDAC), may haveahigherriskforIPMN [25] . Also, several studies have noticed that the presence of autoimmune disease in general population is around 5%; however, in patients diagnosed with IPMN, the number rises up to 22%. IPMNs can be associated with systemic diseases such as: systemiclupuserythematousandrheumatoidarthritisaninflammatoryboweldisease,lead-ingtothinkthatIMPNsmaybeonemanifestationofamoresystemicdisease [26] .
Symptoms
MostIPMNsarediagnosedbetween60and70yearsofage.Thereisaslightlyhigherprevalence in men than women [7] . Some patients present symptoms at the time of diagnosis (7-43%), being more frequent the presence of abdominal pain, jaundice, and previous history of pancreatitis.Othersymptomsareasfollows:weightloss,nauseaorvomiting,anddiabetes [5, 6, 27 ].
Evaluation for malignancy
Several tests can be performed when confronted with a possible IPMN. Regarding this subject,somechangeshaveoccurredrecently,mostofthemcenteringontheuseofEUS-FNA (endoscopic ultrasonography/fine-needle aspiration) and endoscopic retrograde cholangiopancreatography(ERCP)andanalysesoftheobtainedfluid (Figure 3 ).
Cross-sectional imaging
Magnetic resonance cholangiopancreatography (MRCP) and computerized axial tomography scan(CATscan)areusefulasthefirststep,andperhapstheonlyone,ifresultsareveryclear (see management) (Figure 4) . It is useful to describe:
• Anatomical characteristics: lymph node involvement and main pancreatic duct involvement.
• Mural nodules: IPMN with >3 mm nodules is highly suggestive of malignancy. Challenges in Pancreatic Pathology
EUS-FNA
This technique has been evolving, and more hospitals are incorporating it into their routine diagnostic tests, helping to introduce its more general application and obtaining information by:
• Describing sonographic characteristics: mural nodes and invasion.
• Performingpancreaticandcystfluidanalysis:cellularity,CEAdeterminationandmolecu-larmarkersKRASwithorwithoutGNASmutation,TP53,PIK3CA,p16/CDKN21,SMAD4, orPTENmutation (28) .
Onthe2012internationalconsensusguidelines [28] , certain recommendations were made as towhentouseEUS-FNA:
• Pancreatic cysts with worrisome features.
• Pancreatic small cyst with worrisome features.
• >3cmcystswithnoworrisomefeatures,especiallyifelderlypatientstoverifythefindings.
• DistinctionofBD-IPMNversusserouscystneoplasm(SCN)withCEAdetermination.
Nonetheless, the more recent American Gastroenterological Association (AGA) guideline on the management of pancreatic cysts [29] issues a conditional recommendation: "pancreatic cystswithatleasttwohigh-riskfeatures,suchassize≥3cm,adilatedmainpancreaticduct, or the presence of an associated solid component, should be examined with endoscopic ultrasonographywithfine-needleaspiration(EUS-FNA)" (Figure 5) .
Macroscopically, highly viscous fluid is the first clue that the cyst is mucinous cyst. Furthermore, high concentration of CEA reflects the presence of a mucinous epithelium, anditiselevatedinbothIPMNsandMCNs.Thus,itisquitebeneficialtodistinguishmucinouscystsfromnon-mucinous.Acut-offCEAlevelof192ng/mLhasthesensitivityof73%, specificityof84%.Duetoconnectivitytothepancreaticductalsystem,amylaselevelmaybe elevated in IPMNs.
Inconclusion,themostrecentpapersencouragetheuseofEUS-FNAintheinitialdiagnostic
tests [15, 30] to identify smaller cysts with high grade or invasive pathology [30] and to detect mural nodules otherwise missed on cross-sectional imaging or malignant cytology in lesions >3 cm. The high specificity and accuracy of EUS strongly position it as the optimum tool for diagnosing malignant BD-IPMNs, particularly in patients without worrisome features and with smaller cysts [31] .Itisparticularlyimportanttoconsiderthatinherentriskscanbe derived from this test, including complications associated with these endoscopic procedures suchasdifficultyincytologicalinterpretationofsamplesandrelativelylowsensitivity [31] .
Biomarkers
DNA analysis of pancreatic cyst fluid demonstrated that KRAS mutation is highly specific (96%) for mucinous cysts, but the sensitivity is only 45%. KRAS is an early oncogenic mutation in the adenoma-carcinoma sequence but cannot discriminate a benign from malignant mucinous cyst. A recent study [32] demonstrated that the "GNAS mutation detectedincystfluidcanseparateIPMNfromMCN,butsimilartoKRASmutations,it does not predict malignancy. The absence of a GNAS mutation also does not correlate with a diagnosis of MCN because not all IPMNs will demonstrate a GNAS mutation [33] [34] [35] .
AGNASmutationwaspresentin66%ofIPMNs."ButarecentmutationsstudyinGNAS atcodon201hasbeenidentifiedinduodenalfluidsamplesevenbeforetheIPMNlesion, whichwasidentifiedonradiologicimaging [36] . Moreover, one study reports that 33% of incipient IPMNs analyzed have a GNAS mutation, suggesting that a large proportion of incipient IPMNs are part of the IPMN pathway, and these mutations occur early in this process [6, 37] .
A recent study identified glucose and kynurenine to be differentially expressed between non-mucinous and mucinous pancreatic cysts [38] . Metabolic abundances for both were significantlylowerinmucinouscystscomparedwithnon-mucinouscysts.Theclinicalutilityof Figure 5 . UseofEUS-FNAaccordingto2012InternationalConsensusGuidelines [28] and AGA Guidelines [29] .
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Other procedures
ERCP
Forsamplingoffluidbrushesinthe2012InternationalConsensusGuidelinesforthemanage-mentofIPMN,routineuseofthistestwasnotrecommendedandwasleftonlyforscientific purposes [28] . However, as professionals are becoming more familiarized with it and results are increasingly being more accurate, newer studies are encouraging cytology of the pancreatic juice and it is starting to be considered a reliable predictor of malignancy in IPMN [39] . Cytological examination alone is often non-diagnostic due to the low cellularity of the aspiratedfluid.Apositiveornegativediagnosiscanbeobtainedthroughacytologyanalyses witha100%specificity.Moreover,ifahigh-gradeepithelialatypiaisfoundinthecystfluid, it is correlated with an 80% chance of malignancy [40] .
PET scan
Positron emission tomography has been proposed as a useful technique for diagnosing and staging different malignancies. Several studies have investigated the outcomes in IPMN cases, concluding that dual-phase F-18 fluorodeoxyglucose positron emission tomography withcomputedtomography(FDG-PET/CT)hasanoverallspecificityof92-95%andasensi-tivityof88-94%whentryingtodifferentiatemalignantIPMNsvs.benignlesions.Ithasbeen proposedthatPETscansshouldbeperformedinolderpatients,casesatincreasedsurgical risk,orwhenthefeasibilityofparenchyma-sparingsurgerydemandsareliablepreoperative exclusion of malignancy [41, 42] .
Management
To date, three consensus guidelines have been proposed to manage pancreatic cystic lesionsbeginningwiththeoriginal2006Sendaiguideline,whichwasrevisedin2012bythe InternationalAssociationofPancreatology(IAP)inFukuoka,andtherecentAGAguideline [43] [44] [45] .
Allguidesagreethatduetothehigherriskofmalignancy,allsymptomaticcystsshouldbe
further evaluated or resected, depending on the clinical circumstances.
Invasive carcinoma in patients with asymptomatic cysts is very rare, especially in cysts <10 mm. In such cases, no further work-up will be needed; however, follow-up is still recommended [43] [44] [45] [46] .Forbettercharacterizationofthelesions,pancreaticprotocolCTor gadolinium-enhanced MRI with magnetic resonance cholangiopancreatography (MRCP) is recommended for cysts >10 mm [47] . The most recent consensus among radiologists [10] suggests that MRI is preferable for evaluating cysts due to its high-contrast resolution, the identificationofseptum,nodules,andductcommunications.Also,MRIisthepreferable follow-up test because it avoids excessive exposure to radiation [47] .
According to Fukuoka guidelines (1), there are:
• "Worrisome features":
-Cystof≤3cm.
-Thickenedenhancedcystwalls.
-MPD of 5-9 mm.
-Non-enhanced mural nodules.
-Abrupt change in the MPD caliber with distal pancreatic atrophy.
-Lymphadenopathy.
• "High-risk stigmata":
-Obstructivejaundiceinapatientwithacysticlesionofthepancreatichead.
-Enhancedsolidcomponent,MPDsizeof10mm.
All patients with cysts of 3 cm in size without "worrisome features" should undergo surveillance according the size stratification. Patients with cysts of >3 cm and no "worrisome features"canalsobeconsideredforEUStoverifytheabsenceofthickenedwallsormural nodules, particularly if the patient is elderly. All smaller cysts with "worrisome features" shouldbeevaluatedbyEUStofurtherriskstratifythelesion [48] .
Surgery
If surgery is considered for a pancreatic cyst, patients are referred to a center with demonstrated expertise in pancreatic surgery. Surgery is the only treatment option in patients with IPMN of the pancreas with high-grade dysplasia or IPMNs that have progressed to invasive carcinoma (Figure 6) .
Indications
-High-grade dysplasia or Invasive carcinoma.
-High-riskstigmata+positivecytology.
-High-riskstigmataconfirmedbyMRIandEUS.
-Symptomatic cyst.
-Youngerpatientswithcyst>2cmowingtocumulativerisk.
PositivecytologyonEUS-guidedFNAhasthehighestspecificityfordiagnosingmalignancy. Ifthereisacombinationofhigh-riskfeaturesonimaging,thenthisislikelytoincreasethe
Challenges in Pancreatic Pathology [23, 49, 50] ,buthadthebenefitsofsurgeryoutweightherisksinthisselectedpopulation [51] .
The most important aspect of resection is to achieve complete removal of a tumor with a negative margin. If a positive margin is found in a high-grade dysplasia, additional resection of the pancreas should be performed. However, there is no consensus regarding further resection in the case of a low-or moderate-grade dysplasia [51, 52] .
Total pancreatectomy should be contemplated only in younger patients who can manage thecomorbiditiesrelatedtodiabetesandexocrineinsufficiencyorinpatientswithahistory of diabetes [53, 54] . The choice of surgery will be determined by the location of the tumor and the extent of involvement of the gland. It is not clearly established that multifocality correspondstoahigherriskofinvasivecancer;inmostcaseswithmorethanonelesion,the dominant or concerning lesions are resected; and the others are observed with follow-up imaging [1] .
Regarding the BD-IPMN that occurs in elderly patients, the annual malignancy rate is only 2-3%. These factors support a conservative management with follow-up in patients who do not have risk factors predicting malignancy. Younger patients (<65 years) with a cyst size of>2cmmaybecandidatesforresectionowingtothecumulativeriskofmalignancy [27] .
BD-IPMN of >3 cm without these signs can be observed without immediate resection, particularly in elderly patients. The decision needs to be individualized and to depend not only on theriskofmalignancybutalsoonthepatient'sconditionsandcystlocation [51] .
Adjuvant therapy
It has not yet been determined whether or not to offer postresection adjuvant therapy to patientswithIPMNsthathaveprogressedtoinvasivecarcinoma;italsoundefinedastothe optimal strategy for postoperative therapy (chemoradiotherapy versus chemotherapy alone) remainsundefined [55] . A recent study by McMillan et al. [56] suggests that patients classi-fiedasAJCCstageIIthroughIV,presentingwithpositivelymphnodes,positiveresection marginsorpoorlydifferentiatedtumors,maybenefitfromadjuvantchemoradiotherapyover chemotherapyaloneintermsofoverallsurvival,exceptforpatientswhohadAJCCpathologic stage II disease.
Follow-up
TheAGArecommendsdiscussingtherisksandbenefitsofamanagementstrategywiththe patient as a good clinical practice for nearly all diseases and interventions. Patients need to receive a full explanation of all therapeutical options so they can choose the best treatment in accordance with the most recent guidelines. Patients who have a limited life expectancy do notderiveanybenefitfromsurveillance,becauseitisinappropriateforpatientswhoarenot surgical candidates due to severe comorbidities.
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The Fukuoka consensus has high sensitivity of the diagnosis of IPMN and prediction of malignancy [57] ,althoughthecystsizefromthe"high-riskstigmata"to"worrisomefeatures" isstillamatterofcontroversy [57] [58] [59] [60] . A systematic review of the literature suggests that size >3cmincreasedtheriskofmalignancybyapproximately3timesandthepresenceofasolid componentincreasedtheriskofmalignancyapproximatelyeighttimes [58] .
MD-IPMN
Themanagementdependsonthedegreeofductaldilation,≥10mm,iftheductis (Figure 7) -≥10 mm in diameter: resection of MD-IPMN is recommended for patients who have good performance status with reasonable life expectancy. This recommendation is based on the high rate of malignancy in MD-IPMN [28] . 
BD-IPMN
Resectionisgenerallyindicatediftherearehigh-riskstigmataandifpatienthassymptoms attributable to the IPMN. Besides, surgery is indicated if there is evidence of worrisome featuresorpositivecytology.Wemustalwaystakeintoaccountthepatient'sage,lifeexpectancy, and performance status [28] (Figure 8 )
• ≥30 mm: repeat MRCP in 1 year. If the IPMN is stable, continue surveillance with MRCP every 2 years.
• 10-30 mm: repeat MRCP in 1 year. If the IPMN is stable, continue surveillance with MRCP every 2 years. After 5 years, the surveillance interval can be lengthened to every 3 years.
• <10 mm: repeat in 1 year. If the IPMN is stable, continue surveillance with MRCP every 2 years. After 5 years, surveillance can be discontinued.
Follow-upismadeifthepatientisagoodsurgicalcandidate.If,duringsurveillance,thereare changesintheIPMN,aEUS-FNAshouldbeperformed.
MRI is the preferred surveillance imaging modality over computed tomography. The length of surveillance for IPMN is another concern for every clinician. If there is no change in size or characteristics, the AGA suggests that patients without worrisome pancreatic features undergo MRI for surveillance in 1 year and then every 2 years after, for a total of 5 years. The reviewoftheliteraturesuggeststhattheriskofmalignanttransformationofpancreaticcysts isapproximately0.24%peryear.Theriskofcancerincystswithoutasignificantchangeover a 5-year period is lower but this recommendation has very low evidence quality. Therefore, more studies are needed [45] . In addition, the Fukuoka consensus suggests for BD-IPMN follow-up:yearlyfollow-upiflesionis<10mminsize,6-12monthlyfollow-upforlesions between 10 and 20 mm, and 3-6 monthly follow-up for lesions >20 mm [28] . The optimal surveillance approach, however, remains unclear.
Combined main duct and branch duct IPMN
Eachlesionismanaged,asitwouldbeifitweretheonlylesion.
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Surveillance following surgery
• Noninvasive IPMN: the risk of developing a recurrence in the remaining pancreas is at least 5%. So we have to perform the follow-up with MRCP by including a lengthening in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Challenges and New Insights http://dx.doi.org/10.5772/66491 85 the surveillance interval if no changes are detected after several years. If there is another nonresected IPMN, follow-up should continue as stated above [23, 61] .
• Invasive carcinoma: studies say that the risk of IPMN recurrence is 25-50% [62] , and it recommendedsurveillanceevery6months [28] . If we diagnose patients, a recurrence of IPMNwillneedEUSforevaluation.
